Cite

HARVARD Citation

    Ferraresi, V. et al. (2022). Neoadjuvant immune checkpoint inhibitors in high-risk stage III melanoma. Human vaccines & immunotherapeutics. 18 (3), p. . [Online]. 
  
Back to record